OLFM4 and chronic myelogenous leukemia, BCR-ABL1 positive: Knockdown of OLFM4 in CML sCD34+ cells using siRNA potentiated the inhibitory effect of imatinib on CFCs, which was reversed by pretreatment of cells with OLFM4 protein (Fig. 6b).